ID

17380

Descripción

A Phase 3b, Open-Label, Safety and Efficacy Study of Rotigotine as Add-On Therapy With Low Doses of Pramipexole or Ropinirole in Patients With Advanced Parkinson's Disease; ODM derived from: https://clinicaltrials.gov/show/NCT01723904

Link

https://clinicaltrials.gov/show/NCT01723904

Palabras clave

  1. 10/9/16 10/9/16 -
Subido en

10 de septiembre de 2016

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0

Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Advanced Parkinson's Disease NCT01723904

Eligibility Advanced Parkinson's Disease NCT01723904

Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
subject is male or female, aged ≥ 30 and < 80 years at informed consent
Descripción

Age

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0001779
subject has idiopathic parkinson's disease, of more than 3 years duration, as defined by the cardinal sign, bradykinesia, and the presence of at least 1 of the following: resting tremor, rigidity, impairment of postural reflexes, and without any known or suspected cause of parkinsonism
Descripción

parkinson

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0030567
subject has motor fluctuations such as wearing, dyskinesia
Descripción

motor fluctuation

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1868976
subject has experienced nocturias for at least 3 nights within 7 days prior to baseline
Descripción

nocturias

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0028734
subject is taking levodopa (l-dopa, immediate and/or controlled release) in combination with benserazide or carbidopa and has been on a stable dose of l-dopa for at least 28 days prior to baseline (visit 2)
Descripción

levodopa

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0358787
subject is taking a non-ergot dopamine agonist (pramipexole ≤ 1.5 mg/day or ropinirole ≤ 6.0 mg/day) and has been on a stable dose of non-ergot dopamine agonist for at least 28 days prior to baseline (visit 2)
Descripción

non-ergot dopamine agonist

Tipo de datos

boolean

Alias
UMLS CUI [1]
C2917438
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
subject is receiving therapy with tolcapone or budipine
Descripción

tolcapone

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0246330
subject is receiving therapy with one of the following drugs either concurrently or within 28 days prior to baseline (visit 2): alpha-methyl dopa, metoclopramide, reserpine, neuroleptics (except specific atypical neuroleptics: olanzapine, ziprasidone, aripiprazole, clozapine, quetiapine), monoamine oxidase a (mao-a) inhibitors, methylphenidate, or amphetamine
Descripción

alpha-methyl dopa

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0025741
subject has a history of symptomatic (not asymptomatic) orthostatic hypotension within the 6 months prior to baseline (visit 2)
Descripción

orthostatic hypotension

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0020651
subject has a known hypersensitivity to any components of the study medication, such as a history of significant skin hypersensitivity to adhesives, known hypersensitivity to other transdermal medications, or has unresolved contact dermatitis
Descripción

dermatitis

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0011603
subject is pregnant or nursing, or is of child-bearing potential (ie, is (i) not surgically sterile, or, (ii) not using adequate birth control methods [including at least one barrier method] or, (iii) not sexually abstinent, or (iv) not at least 2 years post menopausal)
Descripción

child-bearing potential

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1960468
subject had a previous diagnosis of narcolepsy, sleep apnea syndrome, restless legs syndrome, or periodic limb movement disorder
Descripción

narcolepsy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0027404

Similar models

Eligibility Advanced Parkinson's Disease NCT01723904

Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
Age
Item
subject is male or female, aged ≥ 30 and < 80 years at informed consent
boolean
C0001779 (UMLS CUI [1])
parkinson
Item
subject has idiopathic parkinson's disease, of more than 3 years duration, as defined by the cardinal sign, bradykinesia, and the presence of at least 1 of the following: resting tremor, rigidity, impairment of postural reflexes, and without any known or suspected cause of parkinsonism
boolean
C0030567 (UMLS CUI [1])
motor fluctuation
Item
subject has motor fluctuations such as wearing, dyskinesia
boolean
C1868976 (UMLS CUI [1])
nocturias
Item
subject has experienced nocturias for at least 3 nights within 7 days prior to baseline
boolean
C0028734 (UMLS CUI [1])
levodopa
Item
subject is taking levodopa (l-dopa, immediate and/or controlled release) in combination with benserazide or carbidopa and has been on a stable dose of l-dopa for at least 28 days prior to baseline (visit 2)
boolean
C0358787 (UMLS CUI [1])
non-ergot dopamine agonist
Item
subject is taking a non-ergot dopamine agonist (pramipexole ≤ 1.5 mg/day or ropinirole ≤ 6.0 mg/day) and has been on a stable dose of non-ergot dopamine agonist for at least 28 days prior to baseline (visit 2)
boolean
C2917438 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
tolcapone
Item
subject is receiving therapy with tolcapone or budipine
boolean
C0246330 (UMLS CUI [1])
alpha-methyl dopa
Item
subject is receiving therapy with one of the following drugs either concurrently or within 28 days prior to baseline (visit 2): alpha-methyl dopa, metoclopramide, reserpine, neuroleptics (except specific atypical neuroleptics: olanzapine, ziprasidone, aripiprazole, clozapine, quetiapine), monoamine oxidase a (mao-a) inhibitors, methylphenidate, or amphetamine
boolean
C0025741 (UMLS CUI [1])
orthostatic hypotension
Item
subject has a history of symptomatic (not asymptomatic) orthostatic hypotension within the 6 months prior to baseline (visit 2)
boolean
C0020651 (UMLS CUI [1])
dermatitis
Item
subject has a known hypersensitivity to any components of the study medication, such as a history of significant skin hypersensitivity to adhesives, known hypersensitivity to other transdermal medications, or has unresolved contact dermatitis
boolean
C0011603 (UMLS CUI [1])
child-bearing potential
Item
subject is pregnant or nursing, or is of child-bearing potential (ie, is (i) not surgically sterile, or, (ii) not using adequate birth control methods [including at least one barrier method] or, (iii) not sexually abstinent, or (iv) not at least 2 years post menopausal)
boolean
C1960468 (UMLS CUI [1])
narcolepsy
Item
subject had a previous diagnosis of narcolepsy, sleep apnea syndrome, restless legs syndrome, or periodic limb movement disorder
boolean
C0027404 (UMLS CUI [1])

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial